Elicera Therapeutics receives Chinese patent allowance for ELC-401

PUBT · 1d ago
Elicera Therapeutics receives Chinese patent allowance for ELC-401
  • Elicera Therapeutics received a Chinese notice of allowance for a patent covering its ELC-401 CAR T-cell candidate for glioblastoma.
  • Formal grant is expected shortly, providing exclusive Chinese development and commercialization rights through 2041.
  • The patent covers ELC-401's IL-13Rα2-binding component, complementing existing Chinese patent protection for its iTANK platform.
  • Corresponding patent applications were previously allowed in the United States and granted in Japan.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicera Therapeutics AB published the original content used to generate this news brief via Cision (Ref. ID: 202611050354BITN____UKPR__EN_20261105-BIT-5223-0) on November 05, 2026, and is solely responsible for the information contained therein.